SystImmune, Inc. (SystImmune), a clinical-stage biotechnology company, announced that the FDA has approved its Investigational New Drug (IND) application for BL-M17D1, an antibody-drug conjugate (ADC) with new linker and payload technologies. The IND supports the beginning of a Phase 1 clinical trial, BL-M17D1-ST-101, to examine the safety, tolerability, pharmacokinetics, and preliminary effectiveness of BL-M17D1 for patients with developed solid tumors in the United States. .

SystImmune, Inc. (SystImmune), a clinical-stage biotechnology company, announced that the FDA has approved its Investigational New Drug (IND) application for BL-M17D1, an antibody-drug conjugate (ADC) with new linker and payload technologies. The IND supports the beginning of a Phase 1 clinical trial, BL-M17D1-ST-101, to examine the safety, tolerability, pharmacokinetics, and preliminary effectiveness of BL-M17D1 for patients with developed solid tumors in the United States. .